These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 17130952)

  • 1. [White blood cell lysis syndrome after autologous peripheral blood stem cell transplantation in the treatment of renal AL amyloidosis. Case report].
    Gatica A; Bertin P; Tagle R
    Rev Med Chil; 2006 Jun; 134(6):763-6. PubMed ID: 17130952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
    Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
    Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease.
    Dember LM; Sanchorawala V; Seldin DC; Wright DG; LaValley M; Berk JL; Falk RH; Skinner M
    Ann Intern Med; 2001 May; 134(9 Pt 1):746-53. PubMed ID: 11329232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal impairment due to white-cell lysis after G-CSF and chemotherapy during pediatric autologous stem cell transplantation.
    Malik PS; Bakhshi S
    J Pediatr Hematol Oncol; 2010 Jul; 32(5):416-7. PubMed ID: 20495480
    [No Abstract]   [Full Text] [Related]  

  • 5. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
    Leung N; Dispenzieri A; Fervenza FC; Lacy MQ; Villicana R; Cavalcante JL; Gertz MA
    Am J Kidney Dis; 2005 Aug; 46(2):270-7. PubMed ID: 16112045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of nephrotic syndrome due to systemic AL amyloidosis after autologous stem cell transplantation: renal response is an important therapeutic end point.
    Akay OM; Sahin G; Kabukcuoglu S; Yalcin AU; Gulbas Z
    Clin Nephrol; 2008 Apr; 69(4):294-7. PubMed ID: 18397705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
    Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
    Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients.
    Comenzo RL; Vosburgh E; Simms RW; Bergethon P; Sarnacki D; Finn K; Dubrey S; Faller DV; Wright DG; Falk RH; Skinner M
    Blood; 1996 Oct; 88(7):2801-6. PubMed ID: 8839879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity.
    Worel N; Schulenburg A; Mitterbauer M; Keil F; Rabitsch W; Kalhs P; Gisslinger H; Raderer M; Geissler K; Höcker P; Zielinski CC; Oberbauer R; Greinix HT
    Wien Klin Wochenschr; 2006 Feb; 118(1-2):49-53. PubMed ID: 16489526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
    Scott EC; Heitner SB; Dibb W; Meyers G; Smith SD; Abar F; Kovacsovics T; Perez-Avraham G; Stentz A; Frires R; Dibb J; Maziarz RT
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):424-430.e1. PubMed ID: 24650974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute tumour lysis syndrome: a case in AL amyloidosis.
    Akasheh MS; Chang CP; Vesole DH
    Br J Haematol; 1999 Nov; 107(2):387. PubMed ID: 10583230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease.
    Casserly LF; Fadia A; Sanchorawala V; Seldin DC; Wright DG; Skinner M; Dember LM
    Kidney Int; 2003 Mar; 63(3):1051-7. PubMed ID: 12631087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicentric Castleman disease with secondary AA renal amyloidosis, nephrotic syndrome and chronic renal failure, remission after high-dose melphalan and autologous stem cell transplantation.
    Ogita M; Hoshino J; Sogawa Y; Sawa N; Katori H; Takemoto F; Ubara Y; Hara S; Miyakoshi S; Takaichi K
    Clin Nephrol; 2007 Sep; 68(3):171-6. PubMed ID: 17915620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute renal insufficiency after high-dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation.
    Leung N; Slezak JM; Bergstralh EJ; Dispenzieri A; Lacy MQ; Wolf RC; Gertz MA
    Am J Kidney Dis; 2005 Jan; 45(1):102-11. PubMed ID: 15696449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study.
    Skinner M; Sanchorawala V; Seldin DC; Dember LM; Falk RH; Berk JL; Anderson JJ; O'Hara C; Finn KT; Libbey CA; Wiesman J; Quillen K; Swan N; Wright DG
    Ann Intern Med; 2004 Jan; 140(2):85-93. PubMed ID: 14734330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephrotic syndrome due to primary AL amyloidosis, successfully treated with VAD and subsequent high-dose melphalan followed by autologous peripheral blood stem cell transplantation.
    Gono T; Matsuda M; Dohi N; Hoshi K; Tada T; Sakashita K; Koike K; Aizawa M; Ikeda S
    Intern Med; 2003 Jan; 42(1):72-7. PubMed ID: 12583623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regression of renal amyloid deposits by VAD therapy plus autologous stem cell transplantation in a patient with primary AL amyloidosis.
    Toriu N; Sawa N; Hiramatsu R; Mizuno H; Ikuma D; Sekine A; Hayami N; Sumida K; Yamanouchi M; Hasegawa E; Hoshino J; Takaichi K; Wake A; Ohashi K; Fujii T; Ubara Y
    CEN Case Rep; 2020 Feb; 9(1):6-10. PubMed ID: 31522370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement.
    Madan S; Kumar SK; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Rajkumar SV; Hogan WJ; Leung N; Grogan M; Gertz MA
    Blood; 2012 Feb; 119(5):1117-22. PubMed ID: 22147893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A long-term remission of renal amyloidosis with nephrotic syndrome after autologous peripheral blood stem-cell transplantation.
    Ogawa K; Ikeda K; Furukawa M; Harada-Shirado K; Mashimo Y; Takahashi H; Matsumoto H; Kimura S; Shichishima-Nakamura A; Ohkawara H; Hashimoto Y; Asahi K; Noji H; Ohto H; Takeishi Y
    Fukushima J Med Sci; 2010 Dec; 56(2):151-6. PubMed ID: 21502717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic response after high-dose melphalan and stem cell transplantation in patients with AL amyloidosis associated liver disease.
    Girnius S; Seldin DC; Skinner M; Finn KT; Quillen K; Doros G; Sanchorawala V
    Haematologica; 2009 Jul; 94(7):1029-32. PubMed ID: 19454500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.